HPV vaccine

Administer the first dose of the HPV vaccine series to females at age 11-12 years. 

HPV vaccination is recommended for all females aged <26 years who have not completed the vaccine series. History of genital warts, abnormal Papanicolaou test, or positive HPV DNAtest is not evidence of prior infection with all vaccine HPV types HPV vaccination is still recommended for these persons. 

Ideally, vaccine should be administered before potential exposure to HPV through sexual activity however, females who are sexually active should still be vaccinated. Sexually active females who have not been infected with any of the HPV vaccine types receive the full benefit of the vaccination. Vaccination is less beneficial for females who have already been infected with one or more of the HPV vaccine types. 

Although HPV vaccination is not specifically recommended for females with the medical indications described in Figure 2, Vaccines that might be indicated for adults based on medical and other indications," it is not a live-virus vaccine and can be administered. However, immune response and vaccine efficacy might be less than in persons who do not have the medical indications described or who are immunocompetent. 

Human milk, citric acid in, 6 632t Human papilloma virus (HPV) vaccine, 25 497... 

Gardasil was approved by the FDA in 2006. It is a quadrivalent recombinant vaccine against the human papilloma vims (HPV), more specifically against types 6, 11, 16 and 18. It is able to reduce pre-cancerous cervical, vaginal and vulvar lesions, associated with HPV types 16 and 18, as well as condylomas associated with HPV types 6 and 11. With the approval of the first HPV vaccine, cervical cancer now has a primary prevention tool. 

Human papillomavirus (HPV) infection is a necessary factor in the development of nearly all cases of cervical cancer. A recently approved HPV vaccine, Gardasil, that blocks initial infection with several of the most common sexually transmitted HPV types may lead to significant decreases in the incidence of HPV-induced cancer (see Lowy et ah, 2006). 

But most of the innovative work was still in the early stages, years away from the pharmacists shelves, which meant it could fall through. Others were nice enough products, but hardly blockbuster potential. In one of the jazziest areas of drug research—cancer—Merck s name hardly cropped up at all outside of the HPV vaccine. 

Roden, R. andWu,T.C. (2006) How will HPV vaccines affect cervical cancer ... 

Kawana K, Adachi K, Kojima S, Kozuma S, Fuji T. Therapeutic human papillomavirus (HPV) vaccines a novel approach. Open Virol J. 2012 6 264-9. 

A 19-year-old girl developed several target lesions of the hands and feet 10 days after receiving a second dose of HPV vaccine. The clinical... 

Halligan S, Taylor SA (2007) CT colonography results and limitations. Eur J Radiol 61 400-408 Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452 571 -579 Herzog TJ, Huh WK, Downs LS (2008) Initial lessons learned in HPV vaccination. Gynecol Oncol 109 S4-S11... 

Myers E, Huh WK, Wright JD et al. (2008) The current and future role of screening in the era of HPV vaccination. Gynecol Oncol 109 831-839. Erratum in Gynecol Oncol 110 270... 

The effects of HPV vaccine on pregnancy outcomes (live births, abortions, fetal deaths, and congenital anomalies) have been analysed using postmarketing data from the USA, France, and Canada [28 ]. Among the 517 prospective reports with known outcomes, 451 (87%) were live births, including three sets of twins. Of 454 neonates, 439 (96.7%) were normal. The overall rate of spontaneous abortions was 6.9 per 100 outcomes. The prevalence of major birth defects was 2.2 per 100 live-born neonates. There were seven fetal deaths (1.5 per 100 outcomes). Rates of spontaneous abortions and major birth defects were not greater than in the unexposed population. 

Although no adverse signals have been identified to date, HPV vaccines are not recommended for use in pregnant women. 

Schaffer V, Wimmer S, Rotaru I, Topakian R, Haring H-P, Aichner FT. HPV vaccine a cornerstone of female health a possible cause of ADEM J Neurol 2008 255 1818-20. 

Debeer Ph, De Munter P, Bruyninckx F, Devlieger R. Brachial plexus neuritis following HPV vaccination. Vaccine 2008 26 4417-9. 

---